Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,949.0
-24.5 (-0.82%)

 

  • STI Straits Times Index
    2,949.0
    -24.5 (-0.82%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,577.8
    -3.8 (-0.24%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,980.2
    -1,094.0 (-3.64%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,509.1
    -76.0 (-2.12%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    -
    -
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,241.8
    -47.8 (-0.76%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 2,281.1M
  • Value: 2,309.6M
  • Rise: 109
  • Fall: 262
  • Unch: 403

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
CWX Global0.007+0.002
Thomson Medical0.119-
Oceanus^0.071-0.004
Jiutian Chemical0.089-0.006
SPH1.400+0.120
Secura0.102-0.001
YZJ Shipbldg SGD1.070+0.010
Sembcorp Marine0.153-0.002
Anchor Resources0.015-
ThaiBev0.735-

World Indices

World Indices
Name Last Change
Nasdaq 13,192.3 +72.9
HSI 28,980.2 -1094.0
HSCEI 11,247.2 -470.2
Jakarta 6,241.8 -47.9
Nikkei 225 0.0
SSE Comp 3,509.1 -76.0
Shanghai A 3,678.3 -79.7
Shanghai B 243.4 -2.6
KOSPI 3,012.9 -86.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

CEL-SCI CORP CEL-SCI CORPORATION
Updated on 26 Feb 2021 (End of trading day)
Last (USD): 17.750 Change: -0.610 High: 19.270 Remarks: -
Change (%): -3.32 Low: 17.740
Open 18.500 Yesterday's Close 18.36
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 656,696 Cumulative Value
 
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -3.24071 Trailing EPS (USD) e -3.51643 NAV (USD) b 3.0887
PE a - Trailing PE f - Price / NAV b 5.7468
Dividend (USD) d - Cash In Hand (USD) g 2.3415 Issued & Paid-up Shares c 40,529,300
Dividend Yield (%) d - Price / Cash In Hand g 7.581 Treasury Shares h -
Market Cap (M) 165.714 Enterprise Value (M) 157.548
Piotroski F Score 3 Exchange Code CVM Par Value ( $ ) n.a.
52 Weeks Volatility (%) 101.41 Free Float (%) 94.0
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 16 Feb 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 29 Jul 2015.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CEL-SCI CORP NYSE American 165.714 - - 5.7468 -
Industry Biotechnology NYSE American 173.810 - - 4.2991 -
Local Peer ACTINIUM PHARMACEUTICALS INC NYSE American 644.969 - - 14.1976 -
Local Peer LINEAGE CELL THERAPEUTICS INC NYSE American 344.979 - - 3.7798 -
Local Peer 22ND CENTURY GROUP INC NYSE American 344.246 - - 6.8803 -
Local Peer NANOVIRICIDES INC NYSE American 263.641 - - 9.5022 -
Local Peer IBIO INC NYSE American 163.361 - - 1.5220 -
Local Peer PALATIN TECHNOLOGIES INC NYSE American 119.491 - - 1.7617 -
Local Peer ARMATA PHARMACEUTICALS INC NYSE American 115.190 - - 4.6790 -
Local Peer MATINAS BIOPHARMA HOLDINGS INC NYSE American 111.286 - - 1.7323 -
Local Peer AIM IMMUNOTECH INC NYSE American 91.951 - - 1.5229 -
Local Peer SYNTHETIC BIOLOGICS INC NYSE American 86.362 - - -10.0059 -
Local Peer INDIA GLOBALIZATION CAPITAL INC NYSE American 53.807 - - 2.5061 -
Local Peer ORAGENICS INC NYSE American 50.259 - - 20.4000 -
Other Local Peers CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American)
Global Peer AMGEN INC NASDAQ 129,906.145 17.884 17.884 13.8066 2.849
Global Peer CSL LTD ASX 119,481.601 38.096 31.395 11.3067 1.118
Global Peer GILEAD SCIENCES INC NASDAQ 77,154.626 627.299 627.273 4.2388 4.421
Global Peer ILLUMINA INC NASDAQ 64,109.919 97.729 97.729 13.6579 -
Global Peer MODERNA INC NASDAQ 61,259.865 - - - -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 55,254.498 20.377 20.377 6.3607 -
Global Peer WUXI BIO HKEx 404,384.907 351.767 280.841 27.0708 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 48,270.452 13.740 13.740 4.3782 -
Global Peer BIOGEN INC NASDAQ 41,569.448 10.391 10.391 3.8849 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 33,581.782 55.654 55.654 2.8823 -
Other Global Peers BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), SEAGEN INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), SINO BIOPHARM (HKEx), 10X GENOMICS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), INCYTE CORPORATION (NASDAQ), NOVAVAX INC (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), BIO-TECHNE CORP (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ZAI LAB-SB (HKEx), BRIDGEBIO PHARMA INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), EXELIXIS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), KODIAK SCIENCES INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), BEAM THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), JOINN (HKEx), CHEMOCENTRYX INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), FIBROGEN INC (NASDAQ), Lonza (SGX), PTC THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), ARVINAS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), GENSCRIPT BIO (HKEx), ROCKET PHARMACEUTICALS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ALKERMES PLC (NASDAQ), SEER INC (NASDAQ), VIELA BIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), PRELUDE THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), XENCOR INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), 3SBIO (HKEx), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), LIGAND PHARMACEUTICAL INC (NASDAQ), ALLOVIR INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), NUVATION BIO INC (NYSE), KYMERA THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), OCUGEN INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), DICERNA PHARMACEUTICALS INC. (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), JACOBIO-B (HKEx), JW THERAP-B (HKEx), NGM BIOPHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), BIOATLA INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), PANDION THERAPEUTICS INC (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), TRANSLATE BIO INC (NASDAQ), SHATTUCK LABS INC (NASDAQ), PRECIGEN INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), REGENXBIO INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), VOR BIOPHARMA INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), VIVA BIOTECH (HKEx), HERON THERAPEUTICS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), UNIQURE N.V. (NASDAQ), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), NKARTA INC (NASDAQ), ALPHAMAB-B (HKEx), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUNOVANT INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), MACROGENICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), PERSONALIS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), FRONTAGE (HKEx), HAOHAI BIOTEC (HKEx), BIOXCEL THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), POLYNOVO LIMITED (ASX), OMEROS CORP (NASDAQ), JHBP-B (HKEx), VAXCYTE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MESOBLAST LTD (ASX), ASCENTAGE-B (HKEx), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), MIMEDX GROUP INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), VANDA PHARMACE INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), EPIZYME INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), HUMANIGEN INC (NASDAQ), INHIBRX INC (NASDAQ), PASSAGE BIO INC (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), PROTHENA CORP PLC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), VAXART INC (NASDAQ), CHIMERIX INC (NASDAQ), MERUS B V (NASDAQ), TELIX PHARMACEUTIC (ASX), CURIS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), ATHIRA PHARMA INC (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), KINTOR PHARMA-B (HKEx), KADMON HLDGS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), COMPUGEN (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), AKOUOS INC (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), IMMATICS N V (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), AFFIMED N V (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), ATRECA INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), ALTIMMUNE INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ARDELYX INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), GERON CORP (NASDAQ), SINOMAB BIO-B (HKEx), IVERIC BIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), DPHARMA (Bursa), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), ADICET BIO INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), BIOVIE INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), LEE'S PHARM (HKEx), SESEN BIO INC (NASDAQ), ASCLETIS-B (HKEx), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), UROGEN PHARMA LTD (NASDAQ), OPTHEA LIMITED (ASX), SQZ BIOTECHNOLOGIES CO (NYSE), IMMUNOME INC (NASDAQ), PORTAGE BIOTECH INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), ONCORUS INC (NASDAQ), ATHERSYS INC (NASDAQ), XOMA CORP (NASDAQ), VERASTEM INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), IMUGENE LIMITED (ASX), FORTE BIOSCIENCES INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), ANTEOTECH LIMITED (ASX), T2 BIOSYSTEMS INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), TREVENA INC (NASDAQ), ESSEX BIO-TECH (HKEx), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), NEXTCURE INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), KAMADA LTD (NASDAQ), MEDICINOVA INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), LARIMAR THERAPEUTICS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), CHIASMA INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), IMV INC (NASDAQ), BIONOMICS LTD (ASX), METACRINE INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), INMUNE BIO INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), AXCELLA HEALTH INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), MEDICENNA THERAPEUTICS CORP (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), EQUILLIUM INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), NEXT SCIENCE LTD (ASX), CATALYST BIOSCIENCES INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), IMMUTEP LTD (ASX), HARVARD BIOSCIENCE INC (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), AZIYO BIOLOGICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ORGENESIS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), SIO GENE THERAPIES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), LONGEVERON INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), CONTRAFECT CORP (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), ENZO BIOCHEM INC (NYSE), LEAP THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), SYNLOGIC INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), ARAVIVE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), GALECTIN THERAPEUTICS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), AIKIDO PHARMA INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), LUMOS PHARMA INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), INFLARX N V (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ADVAXIS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), COHBAR INC (NASDAQ), SAVARA INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), UNI-BIO GROUP (HKEx), LEAF RESOURCES LTD (ASX), CLEVELAND BIOLABS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), WINDTREE THERAPEUTICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), VACCINEX INC (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CHIMERIC THERAPEUTICS LTD (ASX), AZURRX BIOPHARMA INC (NASDAQ), REGENT PACIFIC (HKEx), CYNATA THERAPEUTICS LTD (ASX), GENETIC TECHNOLOGIES (ASX), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), VIRIDIAN THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), PLUS THERAPEUTICS INC (NASDAQ), MEMPHASYS LTD (ASX), MICROBOT MEDICAL INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), KIROMIC BIOPHARMA INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), SOLIGENIX INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CT ENTERPRISE (HKEx), BIO-PATH HOLDINGS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), PRECIPIO INC (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), CYCLO THERAPEUTICS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), BIOTRON (ASX), CYCLACEL PHARMACEUTICALS INC (NASDAQ), PATRYS LIMITED (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), Suntar Eco-City (SGX), ADALTA LTD (ASX), BIOSINO BIO-TEC (HKEx), CONTANGO ASSET MANAGEMENT LIMITED (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), HISTOGEN INC (NASDAQ), GEOVAX LABS INC (NASDAQ), CONSTELLATION TECHNOLOGIES LTD (ASX), INMED PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), REGENEUS LTD (ASX), RHINOMED LIMITED (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), BELLICUM PHARMACEUTICALS (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), BRIACELL THERAPEUTICS CORP (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SENESTECH INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), BENITEC BIOPHARMA INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), NANOLLOSE LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), HAO WEN HLDGS (HKEx), CRYOSITE (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --2.090
-10.53 %
10 Days --5.800
-24.63 %
20 Days --7.200
-28.86 %
Medium Term Return 3 Months -+4.810
+37.17 %
6 Months -+4.270
+31.68 %
1 Year -+6.780
+61.80 %
Long Term Return 2 Years -+15.030
+552.57 %
3 Years -+15.900
+859.46 %
5 Years -+2.110
+13.49 %
Annualised Return Annualised --
+2.56 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 8.100 - 40.910 Change From 1 Year Low +9.650 % Change From 1 Year Low (%) +119.14
Change From 1 Year High -23.160 % Change From 1 Year High (%) -56.61
2 Years Range 2.530 - 40.910 Change From 2 Years Low +15.220 % Change From 2 Years Low (%) +601.58
Change From 2 Years High -23.160 % Change From 2 Years High (%) -56.61
5 Years Range 0.817 - 40.910 Change From 5 Years Low +16.933 % Change From 5 Years Low (%) +2073.91
Change From 5 Years High -23.160 % Change From 5 Years High (%) -56.61
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Historical Price Data

Date Open High Low Close Volume VWAP
26 Feb 2021 18.500 19.270 17.740 17.750 656,696 -
25 Feb 2021 19.340 21.230 18.360 18.360 1,053,664 -
24 Feb 2021 18.470 18.940 18.000 18.360 690,741 -
23 Feb 2021 18.000 19.830 18.000 18.060 824,580 -
22 Feb 2021 19.660 19.700 18.230 19.000 839,187 -
19 Feb 2021 19.470 21.000 19.400 19.840 921,171 -
18 Feb 2021 20.180 20.380 19.349 19.370 700,029 -
17 Feb 2021 21.220 21.740 20.000 20.360 885,698 -
16 Feb 2021 24.000 24.230 21.280 21.280 1,205,822 -
12 Feb 2021 22.710 23.750 22.250 23.550 587,470 -
11 Feb 2021 22.850 23.490 22.224 23.060 477,713 -
10 Feb 2021 23.600 24.080 22.010 22.570 760,565 -
09 Feb 2021 24.410 24.850 23.500 23.570 528,042 -
08 Feb 2021 21.640 24.430 21.200 24.430 1,059,519 -
05 Feb 2021 20.970 23.905 20.750 23.590 1,380,484 -
04 Feb 2021 21.160 21.910 20.440 20.970 969,054 -
03 Feb 2021 23.510 23.510 19.550 20.540 1,648,778 -
02 Feb 2021 25.560 25.570 21.635 22.720 1,604,748 -
01 Feb 2021 25.500 27.890 24.340 27.640 2,022,146 -
29 Jan 2021 23.380 26.740 21.540 24.950 3,880,219 -
28 Jan 2021 27.050 35.000 18.680 19.400 5,656,040 -
27 Jan 2021 14.250 40.910 13.950 25.000 14,699,080 -
Summary
Current 2 Weeks
(12 Feb 2021 to 26 Feb 2021)		 22.710 24.230 17.740 17.750 8,365,058 -
Previous 2 Weeks
(29 Jan 2021 to 11 Feb 2021)		 23.380 26.740 17.740 23.060 14,331,268 -
4 Weeks from
(30 Dec 2020 to 28 Jan 2021)		 12.270 24.230 11.900 19.400 31,783,354 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.